semaglutide fda approval date weight loss Approves Oral Semaglutide: First GLP-1 Pill What's New in Obesity Treatment?

Potential Impact on Non-Alcoholic Fatty Liver Disease (NAFLD): Non-alcoholic fatty liver disease is a prevalent condition closely linked to obesity and metabolic disorders

In the Phase 2 clinical trial published in the New England Journal of Medicine, retatrutide results showed participants losing an average of 24.2% of their body weight at the highest dose (12 mg) over 48 weeks

Have already lost a few pounds with my first month

As such, any patient on weight loss or drugs should be very conscious of what they eat and how much they exercise

Seven drug manufacturers had filed with Health Canada, the first in February 2024

That means they are constantly exposed to oxidative stress